Company Overview
American HealthCare Capital is pleased to offer a full spectrum reference laboratory for sale in the Northeast. Established in 2017, this is a state-of-the-art, full-service CLIA certified laboratory. The lab offers the following testing services and capabilities: Prescription Drug Monitoring, Presumptive and Confirmatory Toxicology, and PCR Infectious Disease, Chemistry, Wound, Genetic and Molecular testing.
Financial Overview
The full-service medical and toxicology lab company’s payer mix is approximately 80% Medicaid, 5% Medicare, 10% private insurance, and 5% private pay. Their business mix is 95% Toxicology and 5% Other Testing. 2024 total gross revenues are expected to exceed $6.1 million in 2024 with an adjusted EBITDA of nearly $3 million. Averaging approximately 8,500 Toxicology tests per month, the lab is operating with a gross margin of approximately 36%. It is poised to grow through the expansion of UTI testing to its toxicology base, as well as new test offerings in the Molecular and Genetics sectors.
Staff Overview
The staff is expected to stay on post-acquisition while the owners will assist during a transitional period as needed.
Asking Price
The asking price for this opportunity is $15 million.
